New Evidence Supports a Shift in Prostate Cancer Imaging Researchers in Denmark have found that replacing F-18 sodium fluoride (NaF) PET/CT with F-18 prostate-specific membrane antigen (PSMA) PET/CT could meaningfully influence treatment decisions for men with newly diagnosed high-risk prostate cancer. In a prospective, within-patient comparison, the study suggests that PSMA-PET/CT not only improves diagnostic…